Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
J Am Soc Cytopathol. 2020 May-Jun;9(3):146-151. doi: 10.1016/j.jasc.2019.12.003. Epub 2020 Feb 7.
Lung adenocarcinoma (LADC) is the most common occult primary in patients presenting with a malignant pleural effusion. Distinguishing metastatic LADC from reactive mesothelial cells (RMC) and malignant mesothelioma (MM) based on morphology alone has been a persistent diagnostic challenge in cytopathology. Claudin-4, a major functional constituent of tight junctions, has been shown to help distinguish LADC from RMC and MM in surgical specimens. Our goal was to further validate and assess the utility of Claudin-4 in comparison to BerEP4 and B72.3 in malignant effusions with a focus on metastatic LADC.
We evaluated 58 pleural effusions (40 LADC, 10 RCM, and 8 MM). Immunohistochemistry was performed using Claudin-4, Ber-EP4, and B72.3 on cell blocks. Staining patterns, quantity of tumor cells, and intensity of staining (weak, moderate, or strong) were assessed.
All cases of LADC were positive for Claudin-4 with an overall sensitivity of 100% (40 of 40) and specificity of 100% (18 of 18). In addition, Claudin-4 showed the highest quantity and quality of staining with 3+ staining intensity in 73% (29 of 40) of cases, compared with 35% (14 of 40) of cases using BerEP4 and 52% (21 of 40) of cases using B72.3. The sensitivity and specificity for BerEP4 were 90% and 78%, respectively. The sensitivity and specificity for B72.3 were 87.5% and 100%, respectively.
In this study, Claudin-4 performed superiorly compared to BerEP4 and B72.3 in distinguishing lung adenocarcinoma from RMC or MM in pleural effusions. Our results show Claudin-4 is a useful marker for distinguishing RMC and MM from lung adenocarcinoma, with high sensitivity (100%) and specificity (100%), compatible with studies shown in the literature.
肺腺癌(LADC)是在出现恶性胸腔积液的患者中最常见的隐匿性原发性肿瘤。仅从形态学上区分转移性 LADC 与反应性间皮细胞(RMC)和恶性间皮瘤(MM)一直是细胞病理学中的一个持续诊断难题。 Claudin-4 是紧密连接的主要功能成分之一,已被证明有助于在手术标本中区分 LADC 与 RMC 和 MM。我们的目标是进一步验证和评估 Claudin-4 与 BerEP4 和 B72.3 相比在恶性胸腔积液中的效用,重点是转移性 LADC。
我们评估了 58 例胸腔积液(40 例 LADC、10 例 RMC 和 8 例 MM)。在细胞块上使用 Claudin-4、Ber-EP4 和 B72.3 进行免疫组织化学染色。评估染色模式、肿瘤细胞数量和染色强度(弱、中或强)。
所有 LADC 病例均对 Claudin-4 呈阳性,总体敏感性为 100%(40/40),特异性为 100%(18/18)。此外,Claudin-4 显示出最高的肿瘤细胞数量和质量,73%(29/40)的病例显示 3+染色强度,而 BerEP4 为 35%(14/40),B72.3 为 52%(21/40)。BerEP4 的敏感性和特异性分别为 90%和 78%。B72.3 的敏感性和特异性分别为 87.5%和 100%。
在这项研究中,Claudin-4 在区分胸腔积液中的肺腺癌与 RMC 或 MM 方面的表现优于 BerEP4 和 B72.3。我们的结果表明 Claudin-4 是区分 RMC 和 MM 与肺腺癌的有用标志物,具有高敏感性(100%)和特异性(100%),与文献中的研究结果一致。